Alzheimer’s Drug Discovery Foundation Conference Presentation October 2021

Oct 13, 2021 | News

https://marvelbiotechnology.com/wp-content/uploads/2021/10/ADDF.mp4...

Marvel Biosciences Corp. to Present at the 22nd International Conference on Alzheimer’s Drug Discovery

Sep 17, 2021 | News

Calgary, Alberta–(Newsfile Corp. – September 17, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc.(collectively the”Company”or”Marvel”), is pleased to announce that it has...

Marvel Biosciences Corp. Updates Market on Its Lead Caffeine Inspired Asset MB-204 for Neurological Diseases

Aug 5, 2021 | News

Calgary, Alberta–(Newsfile Corp. – August 5, 2021) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to provide an update on...

Marvel Biosciences Corp. Retains Virtus Advisory Group To Provide Corporate Communications Services

Aug 3, 2021 | News

2021-08-03 17:38 ET – News Release Mr. J. Roderick (Rod) Matheson reports MARVEL BIOSCIENCES CORP. RETAINS VIRTUS ADVISORY GROUP TO PROVIDE CORPORATE COMMUNICATIONS SERVICES Marvel Biosciences Corp. has retained Virtus Advisory Group Inc. to develop and...

Marvel Biosciences Corp. To Commence CGMP Manufacturing Of Its Lead Asset MB-204

Jul 21, 2021 | News

2021-07-21 12:37 ET – News Release Dr. Mark Williams reports MARVEL BIOSCIENCES CORP. TO COMMENCE CGMP MANUFACTURING OF ITS LEAD ASSET MB-204 Marvel Biosciences Corp.’s wholly owned subsidiary Marvel Biotechnology Inc. has achieved a significant science...

Alphanco Venture Corp. Changes Name To Marvel Biosciences Corp. And Completes Acquisition Of Marvel Biotechnology Inc.

Jul 8, 2021 | News